Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Kirby Institute

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Private

Established: 1986-01-01

Employees: 101

Market Cap: -

Website: https://kirby.unsw.edu.au

Clinical Trials

Pravastatin for Hyperlipidaemia in HIV.

Phase 4

Completed

Conditions: HIV Infections
Lipid Metabolism
Glucose Metabolism
Metabolic Abnormality
Lipodystrophy
Cardiovascular Disease

First Posted Date: 2005-09-28

Last Posted Date: 2006-06-09

Lead Sponsor: Kirby Institute

Target Recruit Count: 40

Registration Number: NCT00227500

Locations: 🇦🇺
St. Vincents Hospital, Sydney, New South Wales, Australia

Tenofovir in HIV/HBV Coinfection

Phase 4

Completed

Conditions: Hepatitis B Coinfection
HIV Infection

Interventions: Drug: Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)
Drug: Tenofovir

First Posted Date: 2005-09-19

Last Posted Date: 2015-04-01

Lead Sponsor: Kirby Institute

Target Recruit Count: 36

Registration Number: NCT00192595

Locations: 🇦🇺
St. Vincent's Hospital, Darlinghurst, New South Wales, Australia
🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia
🇹🇭
Thai Red Cross AIDS Research Centre, Bangkok, Thailand

Australian Trial in Acute Hepatitis C

Phase 4

Completed

Conditions: Hepatitis C

Interventions: Drug: Pegylated Interferon alfa 2a
Drug: Ribavirin (HIV conifected patients only)

First Posted Date: 2005-09-19

Last Posted Date: 2011-04-15

Lead Sponsor: Kirby Institute

Target Recruit Count: 167

Registration Number: NCT00192569

Locations: 🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺
407 Doctors, Darlinghurst, New South Wales, Australia
🇦🇺
Holdsworth House GP Practice, Darlinghurst, New South Wales, Australia

and more 14 locations

HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)

Phase 4

Completed

Conditions: HIV-Associated Lipodystrophy Syndrome
Cardiovascular Disease

First Posted Date: 2005-09-19

Last Posted Date: 2012-04-12

Lead Sponsor: Kirby Institute

Target Recruit Count: 80

Registration Number: NCT00192660

Locations: 🇦🇺
St. Vincent's Hospital, Sydney, New South Wales, Australia

A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Abacavir 600mg - Lamivudine 300mg
Drug: Emtricitabine 200mg - Tenofovir 300mg

First Posted Date: 2005-09-19

Last Posted Date: 2011-05-25

Lead Sponsor: Kirby Institute

Target Recruit Count: 357

Registration Number: NCT00192634

Locations: 🇦🇺
Holdsworth House General Practice - Byron Bay, Byron Bay, New South Wales, Australia
🇦🇺
Lismore Sexual Health Clinic - Northen Rivers Area Health Service, Lismore, New South Wales, Australia
🇦🇺
John Hunter Hospital, Newcastle, New South Wales, Australia

and more 28 locations

A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation: the ASK-500 Study

Not Applicable

Completed

Conditions: HIV Infections

Interventions: Drug: saquinavir 500 formulation
Drug: cross-over arm

First Posted Date: 2005-09-19

Last Posted Date: 2009-06-26

Lead Sponsor: Kirby Institute

Target Recruit Count: 40

Registration Number: NCT00192608

Locations: 🇦🇺
St Vincents Hospital, Sydney, New South Wales, Australia

Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects

Phase 4

Completed

Conditions: Lipodystrophy
Cardiovascular Disease
Glucose Metabolism Disorders
Metabolic Diseases
HIV Infections
Dyslipidemias

First Posted Date: 2005-09-19

Last Posted Date: 2012-04-12

Lead Sponsor: Kirby Institute

Target Recruit Count: 50

Registration Number: NCT00192621

Locations: 🇦🇺
St Vincents Hospital, Sydney, New South Wales, Australia

Toxicity Substudy of Evaluation of Subcutaneous Proleukin in a Randomised International Trial (ESPRIT): TOXIL-2 Substudy

Phase 3

Terminated

Conditions: HIV Infections

Interventions: Drug: Ondansetron, ibuprofen, paracetamol
Drug: Metoclopramide, codeine phosphate, ibuprofen, paracetamol
Drug: metoclopramide, ibuprofen, paracetamol

First Posted Date: 2005-09-07

Last Posted Date: 2012-04-12

Lead Sponsor: Kirby Institute

Target Recruit Count: 28

Registration Number: NCT00147355

Locations: 🇦🇷
Hospital General de Agudos JM Ramos Mejia, Buenos Aires, Argentina
🇦🇷
FUNCEI, Buenos Aires, Argentina
🇦🇷
Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

and more 13 locations

Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy

Phase 4

Terminated

Conditions: HIV-Associated Lipodystrophy
HIV Infections

Interventions: Device: poly-L-lactic acid

First Posted Date: 2005-08-03

Last Posted Date: 2009-04-02

Lead Sponsor: Kirby Institute

Target Recruit Count: 100

Registration Number: NCT00126308

Locations: 🇦🇺
Dr Doong's Surgery, Burwood, New South Wales, Australia
🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇦🇺
407 Doctors, Sydney, New South Wales, Australia

and more 15 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy